Developer docs
API playgroundTry for free, no card

Search company profiles

Translumina Therapeutics

Full company profile

uuid0002eis

Namestring
Translumina Therapeutics
Legal namestring
Translumina
Websiteurl
translumina.in
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Translumina Therapeutics is a manufacturer of interventional cardiovascular medical devices, headquartered in New Delhi, India, and described as India's largest domestic player in the coronary stents market. Founded in 2010, the company produces a four-category product portfolio: drug-eluting stents (including a proprietary Polymer-Free DES positioned as a breakthrough in stent safety), the Protege drug-eluting balloon, coronary balloons, and vascular accessories. Manufacturing is conducted across three ISO 13485:2016 certified facilities in Dehradun (India), Hechingen (Germany), and Helmond (Netherlands), serving hospitals, cardiac centers, and interventional cardiologists in 40+ countries with a workforce of 600+ employees.

The company generates revenue through direct hardware sales of cardiovascular devices to healthcare providers via an enterprise field-sales model, with quote-based, negotiated procurement typical of the medical device category. Translumina supplements its direct sales with KOL-targeted medical education programs including the TransAcademy platform, Expert Sessions, and webinar series such as 'IVL Unplugged' (with Shockwave) and 'Crossing Conversations in CTOs.' The product ecosystem is extended through strategic partnerships with Shockwave (IVL), SIS Medical, ACIST (intravascular imaging), and Asahi Intecc (guidewires and catheters).

Translumina's recent corporate activity indicates an active globalization strategy: two European acquisitions were completed in June 2023 (Blue Medical Devices in the Netherlands and Lamed), the company established direct operations in the UAE in May 2024, and MedTech veteran Probir Das was appointed CEO in October 2024. The company remains privately held, with Everstone disclosed as a significant growth-equity investor from a 2019 funding round of approximately $69.9 million.

Short descriptiontext

Translumina Therapeutics is an India-headquartered manufacturer of interventional cardiovascular medical devices, including drug-eluting stents, drug-eluting balloons, and coronary balloons. Operating three ISO 13485:2016 certified facilities in India, Germany, and the Netherlands, it serves hospitals and interventional cardiologists in 40+ countries as India's largest domestic coronary stent player.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNew Delhi, India
HQ citystring
New Delhi
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
interventional cardiovascular devices, drug-eluting stents, cardiovascular medical devices, coronary intervention products, polymer-free stent technology
Industry2 codes
PRIMARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Interventional Cardiovascular Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cardiovascular Medical Devices Sales
TypeHardware Sales
Description

Sale of interventional cardiovascular devices including drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories to healthcare providers globally.

translumina.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1TransAcademy
Description

Educational/training platform for medical professionals

translumina.com
Core offering1 text field

Translumina Therapeutics designs, develops, and manufactures interventional cardiovascular medical devices, including drug-eluting stents (featuring proprietary polymer-free technology), drug-eluting balloons (Protege), coronary balloons, and vascular accessories. The company sells these products to hospitals, cardiac centers, and interventional cardiologists globally through direct enterprise sales channels.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Translumina Therapeutics is a global leader in interventional cardiovascular devices offering a comprehensive portfolio of four core product categories: Drug Eluting Stents (including polymer-free technology), Drug Eluting Balloons (Protege), Coronary Balloons, and Vascular Accessories. The company operates manufacturing facilities in India, Germany, and the Netherlands, serving 40+ countries with ISO 13485:2016 certified quality standards.

Product and service4 records
1Drug Eluting Stents
CategoryDrug-Eluting Stents
Description

State-of-the-art drug-eluting stents for cardiovascular care, featuring polymer-free technology that redefines performance and improves stent safety, intended for hospitals and interventional cardiologists performing percutaneous coronary interventions.

2Drug Eluting Balloons (Protege)
CategoryDrug-Eluting Balloons
Description

Cutting-edge drug-eluting balloons for vascular treatment, enabling localized drug delivery during percutaneous coronary interventions, targeted at interventional cardiology departments.

3Coronary Balloons
CategoryCoronary Balloons
Description

Advanced coronary balloons for cardiovascular interventions, designed for optimal trackability and inflation performance during angioplasty procedures, used by interventional cardiologists.

4Vascular Accessories
CategoryVascular Accessories
Description

Precision vascular accessories supporting cardiovascular interventions, designed to achieve exceptional clinical outcomes in catheterization labs and interventional cardiology settings.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-29
Description

Translumina acquired Blue Medical Devices, Netherlands in June 2023 to further strengthen its technology portfolio, expanding capabilities in the European market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-07
Description

Translumina acquired Lamed to extend its European reach, expanding distribution and market presence in Europe.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership for intravascular lithotripsy (IVL) technology and co-marketing initiatives including 'IVL Unplugged' webinar series.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership for cardiovascular intervention technologies under the strategic partnerships section of the website.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership for intravascular imaging and diagnostic technologies in cardiovascular care.

6Asahi Intecc
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Strategic partnership for advanced guidewire and catheter technologies supporting complex cardiovascular interventions.

translumina.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers6 records
TypeDirect peer
Description

Indian manufacturer of drug-eluting stents and cardiovascular devices, directly competing with Translumina in India's coronary stent market and several emerging markets. Closest head-to-head domestic competitor.

TypeDirect peer
Description

Indian interventional cardiology device manufacturer producing DES (Meerabi), balloons, and structural heart products. Directly comparable in product portfolio, scale, and emerging-market GTM approach.

3Abbott
TypeBroad incumbent
Description

Global medtech leader with the Xience DES franchise — the gold-standard DES against which Translumina's polymer-free stent must compete. Dominant share in developed markets and clinical-evidence incumbent.

TypeBroad incumbent
Description

Owner of the Synergy/Promus DES platform and other interventional cardiology franchises; sets competitive benchmarks in DES innovation, clinical evidence, and physician engagement globally.

TypeBroad incumbent
Description

Major DES competitor with Resolute and Onyx platforms; large global interventional cardiology portfolio with deep KOL and clinical-trial infrastructure that Translumina must leverage or compete against.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Translumina Therapeutics

Interventional Cardiovascular Devicestranslumina.in

Translumina Therapeutics is an India-headquartered manufacturer of interventional cardiovascular medical devices, including drug-eluting stents, drug-eluting balloons, and coronary balloons. Operating three ISO 13485:2016 certified facilities in India, Germany, and the Netherlands, it serves hospitals and interventional cardiologists in 40+ countries as India's largest domestic coronary stent player.

What Translumina Therapeutics does

Translumina Therapeutics is a manufacturer of interventional cardiovascular medical devices, headquartered in New Delhi, India, and described as India's largest domestic player in the coronary stents market. Founded in 2010, the company produces a four-category product portfolio: drug-eluting stents (including a proprietary Polymer-Free DES positioned as a breakthrough in stent safety), the Protege drug-eluting balloon, coronary balloons, and vascular accessories. Manufacturing is conducted across three ISO 13485:2016 certified facilities in Dehradun (India), Hechingen (Germany), and Helmond (Netherlands), serving hospitals, cardiac centers, and interventional cardiologists in 40+ countries with a workforce of 600+ employees.

The company generates revenue through direct hardware sales of cardiovascular devices to healthcare providers via an enterprise field-sales model, with quote-based, negotiated procurement typical of the medical device category. Translumina supplements its direct sales with KOL-targeted medical education programs including the TransAcademy platform, Expert Sessions, and webinar series such as 'IVL Unplugged' (with Shockwave) and 'Crossing Conversations in CTOs.' The product ecosystem is extended through strategic partnerships with Shockwave (IVL), SIS Medical, ACIST (intravascular imaging), and Asahi Intecc (guidewires and catheters).

Translumina's recent corporate activity indicates an active globalization strategy: two European acquisitions were completed in June 2023 (Blue Medical Devices in the Netherlands and Lamed), the company established direct operations in the UAE in May 2024, and MedTech veteran Probir Das was appointed CEO in October 2024. The company remains privately held, with Everstone disclosed as a significant growth-equity investor from a 2019 funding round of approximately $69.9 million.

Translumina Therapeutics firmographics

Firmographics
Name
Translumina Therapeutics
Legal name
Translumina
Website
https://translumina.in
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
251–500 employees
Short description
Translumina Therapeutics is an India-headquartered manufacturer of interventional cardiovascular medical devices, including drug-eluting stents, drug-eluting balloons, and coronary balloons. Operating three ISO 13485:2016 certified facilities in India, Germany, and the Netherlands, it serves hospitals and interventional cardiologists in 40+ countries as India's largest domestic coronary stent player.
Ownership category
akta.pro rank

Translumina Therapeutics industry classification

Industry
Product category
Interventional Cardiovascular Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Interventional cardiovascular devices
  • Drug-eluting stents
  • Cardiovascular medical devices
  • Coronary intervention products
  • Polymer-free stent technology

Where Translumina Therapeutics is headquartered

Location

Headquarters

HQ city
New Delhi
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Translumina Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Cardiovascular Medical Devices Sales: Sale of interventional cardiovascular devices including drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories to healthcare providers globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Translumina Therapeutics product offering

Product offering

Core offering

Translumina Therapeutics designs, develops, and manufactures interventional cardiovascular medical devices, including drug-eluting stents (featuring proprietary polymer-free technology), drug-eluting balloons (Protege), coronary balloons, and vascular accessories. The company sells these products to hospitals, cardiac centers, and interventional cardiologists globally through direct enterprise sales channels.

Product overview

Translumina Therapeutics is a global leader in interventional cardiovascular devices offering a comprehensive portfolio of four core product categories: Drug Eluting Stents (including polymer-free technology), Drug Eluting Balloons (Protege), Coronary Balloons, and Vascular Accessories. The company operates manufacturing facilities in India, Germany, and the Netherlands, serving 40+ countries with ISO 13485:2016 certified quality standards.

Differentiator

Problem solved

Functional benefit

Brands

  • TransAcademy: Educational/training platform for medical professionals

Products and services

  • Drug Eluting Stents State-of-the-art drug-eluting stents for cardiovascular care, featuring polymer-free technology that redefines performance and improves stent safety, intended for hospitals and interventional cardiologists performing percutaneous coronary interventions.
  • Drug Eluting Balloons (Protege) Cutting-edge drug-eluting balloons for vascular treatment, enabling localized drug delivery during percutaneous coronary interventions, targeted at interventional cardiology departments.
  • Coronary Balloons Advanced coronary balloons for cardiovascular interventions, designed for optimal trackability and inflation performance during angioplasty procedures, used by interventional cardiologists.
  • Vascular Accessories Precision vascular accessories supporting cardiovascular interventions, designed to achieve exceptional clinical outcomes in catheterization labs and interventional cardiology settings.

Companies that use Translumina Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Translumina Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Translumina Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • Blue Medical DevicescoreStrategic or Co-development Partner · 29 June 2023Translumina acquired Blue Medical Devices, Netherlands in June 2023 to further strengthen its technology portfolio, expanding capabilities in the European market.
  • LamedcoreStrategic or Co-development Partner · 7 June 2023Translumina acquired Lamed to extend its European reach, expanding distribution and market presence in Europe.
  • ShockwavemajorStrategic or Co-development PartnerStrategic partnership for intravascular lithotripsy (IVL) technology and co-marketing initiatives including 'IVL Unplugged' webinar series.
  • SIS MedicalmajorStrategic or Co-development PartnerStrategic partnership for cardiovascular intervention technologies under the strategic partnerships section of the website.
  • ACISTmajorStrategic or Co-development PartnerStrategic partnership for intravascular imaging and diagnostic technologies in cardiovascular care.
  • Asahi InteccmajorStrategic or Co-development PartnerStrategic partnership for advanced guidewire and catheter technologies supporting complex cardiovascular interventions.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Translumina Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sahajanand Medical Technologies: Indian manufacturer of drug-eluting stents and cardiovascular devices, directly competing with Translumina in India's coronary stent market and several emerging markets. Closest head-to-head domestic competitor.
  • Meril Life Sciences: Indian interventional cardiology device manufacturer producing DES (Meerabi), balloons, and structural heart products. Directly comparable in product portfolio, scale, and emerging-market GTM approach.

Broad incumbents

  • Abbott: Global medtech leader with the Xience DES franchise — the gold-standard DES against which Translumina's polymer-free stent must compete. Dominant share in developed markets and clinical-evidence incumbent.
  • Boston Scientific: Owner of the Synergy/Promus DES platform and other interventional cardiology franchises; sets competitive benchmarks in DES innovation, clinical evidence, and physician engagement globally.
  • Medtronic: Major DES competitor with Resolute and Onyx platforms; large global interventional cardiology portfolio with deep KOL and clinical-trial infrastructure that Translumina must leverage or compete against.

Peers

Market position

Strengths4 records

Weaknesses3 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Translumina Therapeutics social profiles

Digital presence

Translumina Therapeutics compliance and trust

Trust signal

Compliance1 record

Translumina Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Translumina Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Translumina Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Translumina Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Translumina Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Translumina Therapeutics

What does Translumina Therapeutics do?

Translumina Therapeutics designs, develops, and manufactures interventional cardiovascular medical devices, including drug-eluting stents (featuring proprietary polymer-free technology), drug-eluting balloons (Protege), coronary balloons, and vascular accessories. The company sells these products to hospitals, cardiac centers, and interventional cardiologists globally through direct enterprise sales channels.

Is Translumina Therapeutics a public or private company?

Translumina Therapeutics is a private company. It is classified as private equity controlled and is currently operating.

When was Translumina Therapeutics founded?

Translumina Therapeutics was founded in 2010. It employs 251 to 500 people.

Where is Translumina Therapeutics based?

Translumina Therapeutics is headquartered in New Delhi, India, in the Asia region.

How does Translumina Therapeutics make money?

One revenue line is on record: cardiovascular Medical Devices Sales.

Who are Translumina Therapeutics's main competitors?

Direct peers on record are Sahajanand Medical Technologies and Meril Life Sciences. Broad incumbents are Abbott, Boston Scientific and Medtronic. Biotronik is listed as a peer.

Does Translumina Therapeutics have an API?

No public API is recorded for Translumina Therapeutics.

What industry is Translumina Therapeutics in?

Translumina Therapeutics's product category is Interventional Cardiovascular Devices. Its primary akta.pro industry code is HLAHAFAA, Coronary Stents & Drug-Eluting Technologies, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comOverview of Segmentation, Market Dynamics, and Competitive Landscape in the Congenital Heart Defect Devices MarketThe global congenital heart defect devices market is projected to reach $4.45 billion by 2030, growing at a compound annual growth rate of 7.4%, driven by increased demand for early diagnosis, minimally invasive pediatric cardiac procedures, and innovations in implantable devices. In June 2023, India-based Translumina Therapeutics LLP acquired the Netherlands-based Wellinq Group Company to expand its cardiovascular and endovascular product portfolio. Additionally, in May 2024, Indian manufacturer Sahajanand Medical Technologies entered a strategic partnership with HeartX to integrate the JOVE VB Stent into its congenital heart defect device offerings.PR NewswireTranslumina stärkt seine deutsche Präsenz durch die Übernahme der Lamed GmbHTranslumina has acquired Lamed GmbH, a Munich-based market access platform for vascular and cardiovascular products, to strengthen its presence in the German medical device market. The acquisition provides Translumina with access to Lamed's network covering over 1,000 hospitals through a Group Purchasing Organization (GPO), facilitating the introduction of its product portfolio in Europe's largest interventional cardiology market.Ani NewsTranslumina bolsters its German presence with acquisition of Lamed GmbHTranslumina announced the acquisition of Munich-based Lamed GmbH on June 7, strengthening its presence in Germany's cardiovascular medical device market. This strategic acquisition aims to enhance Translumina's ability to provide a comprehensive cardiovascular portfolio across key global markets, leveraging Lamed's established relationships in over 1,000 hospitals.PR NewswireTranslumina fortalece aún más el liderazgo sénior para impulsar su siguiente fase de crecimientoTranslumina, a global cardiovascular medical device developer and manufacturer, announced the appointment of Indranil Mukherjee as Group Chief Executive Officer and Armin Kiser as Managing Director and Chief Operating Officer for Europe, effective immediately. Mukherjee joins from B. Braun Group India where he served as managing director overseeing three production plants and over 2,000 employees, while Kiser previously served as COO of Biedermann Motech and plant leader at Edwards Lifesciences in Switzerland. The leadership reinforcements are aimed at accelerating Translumina's next growth phase, which includes expanding into specialized balloons and structural heart segments with transcatheter solutions for mitral, aortic, and tricuspid valves.PR NewswireTranslumina refuerza la dirección para impulsar la siguiente fase de crecimientoTranslumina appointed Indranil Mukherjee as Group CEO and Armin Kiser as Managing Director and Head of Operations for its European business to drive its next phase of growth. The new leadership team aims to expand the company's global presence in interventional cardiovascular devices, leveraging Translumina's R&D base in Germany and manufacturing capabilities in India.